
Developer of Functional Membrane for Biological Tissues and Derived Medical Devices

Equity Investment Institution

Equity Investment Management Company

Preface
Preface
Recently,Daotong Family Enterprise——Bochuang Biotech(hereinafter referred to as "Bochuang Biotech")Successfully Completed Pre-A Round Financing of Tens of Millions of YuanThis round of financing was led by Hangzhou Huafang Capital, with follow-up investments from TigerYeah Capital, BMC, and Suzhou Industrial Park Leading Entrepreneurship Investment.This is Bochuang Biotech's third financing in nearly two years.

Bochuang Biotech was founded in June 2022. It is a national high-tech enterprise, a technology-oriented private enterprise in Jiangsu Province, and a leading entrepreneurial talent enterprise in Gusu and the industrial park. Its core technology mainly originates from the team led by Academician Changsheng Liu. Leveraging the technical and talent advantages of its founding team, Bochuang Biotech will develop a series of high-end innovative products such as artificial corneas and periosteum based on the internationally pioneering "Electrochemical Deposition of Biomacromolecules" (EDP) technology platform. The company is committed to promoting the upgrading and replacement of collagen repair products and membrane repair products in China.
Core Product of the Company: Collagen Artificial Cornea (E-Col). With its unique advantages of reducing host immune rejection, preventing neovascularization, and avoiding material opacity, it maintains high transparency during its service life, significantly improving the success rate of corneal repair. It has currently entered the preclinical animal evaluation stage and is expected to undergo clinical trials next year.
It is worth mentioning that the artificial cornea (E-COL) prepared by Bochuang Biotech using EDP technology compensates for the shortcomings of current artificial corneas on the market.EDP technology has overcome the technical challenges of traditional film-making methods, where transparency, uniformity, orientation, curvature, and thickness could not be precisely controlled. Moreover, the raw material for E-COL corneas comes from the company's self-developed collagen products, which exhibit stronger repair activity, higher purity, better safety, and light transmittance exceeding 95%.。

Since its establishment two years ago, Bochuang Biotech has continuously made breakthroughs in technology research and development. It has now built an integrated R&D and production platform that includes raw material R&D, raw material production, product customization, concept verification, manufacturing, and product testing. The company is equipped with more than a hundred devices for extraction, synthesis, processing, and testing. It also has comprehensive R&D laboratories, cell evaluation labs, animal evaluation labs, and a Grade 10,000 clean GMP workshop, providing strong support for the smooth progress of R&D work. To date, Bochuang Biotech has established a relatively complete technical barrier, having obtained six authorized patents and applied for more than ten patents.
In November this year, the Office of the National Leading Group for the Recognition and Management of High-tech Enterprises, in accordance with the relevant provisions of the "Administrative Measures for the Recognition of High-tech Enterprises" (Guo Ke Fa Huo [2016] No. 32) and the "Guidelines for the Recognition and Management of High-tech Enterprises" (Guo Ke Fa Huo [2016] No. 195), announced the filing and public display of the first batch of high-tech enterprises recognized and reported in Jiangsu Province in 2024.Bochuang Biotech Successfully Awarded the Title of National High-Tech EnterpriseThis honor is not only an authoritative recognition of Bochuang Biotech's strength in the field of biomaterials technology, but also the best proof of its long-term commitment to the innovation-driven development strategy.

Regarding the acquisition of this round of financing,Bochuang BiotechExpressed: Thanks for the support and recognition from the investment institutions in this round. The company will make full use of the financing funds to further accelerate the R&D progress of Bochuang Biotech's existing products such as artificial cornea and artificial bone membrane. Meanwhile, it will further increase the R&D investment in the fields of collagen raw materials and the controllable electrochemical assembly technology of biological macromolecules, optimizing and supplementing the existing product line.
END



ID:daltonventure
Long press to follow
R E C O M M E N D E D R E A D I N G


